Marta Maria Bednarek

Dr. Marta Maria Bednarek

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KKKlaudia Kubiak
Klaudia Kubiak
JBJoanna Bidzinska
Joanna Bidzinska
MBMarta Maria Bednarek
Marta Maria Bednarek
Edyta SzurowskaEdyta Szurowska
Edyta Szurowska
Breast cancer remains the most frequently diagnosed malignancy in women worldwide, accounting for approximately 2.3 million new cases and 670,000 deaths annually. The diagnostic landscape has undergone a paradigm shift over the past two decades, evolving from morphology-based classification toward molecularly informed, precision-guided strategies. Early and accurate diagnosis is fundamental to improving outcomes; advances in imaging technology, including digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), and abbreviated magnetic resonance imaging (MRI), have improved sensitivity and specificity in diverse patient populations. Simultaneously, the integration of artificial intelligence (AI) and radiomics into screening workflows offers unprecedented potential for risk stratification and a reduction in false-positives. At the pathological level, multi-gene expression profiling assays such as Oncotype DX, MammaPrint, Prosigna, and EndoPredict have refined prognostic classification and guide adjuvant chemotherapy decisions in early-stage hormone receptor-positive disease. The emergence of liquid biopsy, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomal biomarkers provides minimally invasive tools for real-time monitoring of response, residual disease, and the evolution of resistance mechanisms. Precision diagnostics now encompass next-generation sequencing (NGS)-based comprehensive genomic profiling, enabling identification of actionable alterations such as PIK3CA mutations, HER2 amplification, BRCA1/2 pathogenic variants, and NTRK fusions, each linked to approved therapeutic agents. The purpose of this review is to provide a comprehensive synthesis of current and emerging diagnostic modalities in breast cancer—from population-level screening to individualized molecular profiling—and to examine how integrative, multimodal diagnostic platforms are reshaping clinical decision-making in the era of precision medicine.

1 July 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KGKlaudia Gutowska
Klaudia Gutowska
AKAnna Kucinska-Chahwan
Anna Kucinska-Chahwan
MBMarta Maria Bednarek
Marta Maria Bednarek
AJAnna Jelitto
Anna Jelitto
RPRadosław Pietrzak
Radosław Pietrzak
TITadeusz Issat
Tadeusz Issat
Congenital cytomegalovirus (cCMV) is the leading infectious cause of long-term neuro-sensory impairment. Aim of meta-analysis was to evaluate the efficacy of antenatal immunoglobulin therapy—particularly cytomegalovirus-specific hyperimmune globulin (HIG)—in preventing vertical transmission and congenital cytomegalovirus infection (cCMV) in pregnancies complicated by primary maternal CMV infection. A search of PubMed, Cochrane Library, Embase, Scopus, ScienceDirect, Taylor & Francis Online, Wiley Online Library, ClinicalTrials.gov, and Google Scholar identified randomized controlled trials, prospective or retrospective cohort studies including pregnant women with serologically confirmed primary CMV infection. Eligible interventions included antenatal CMV-specific or nonspecific immunoglobulins (vs placebo, usual care, historical controls, or no treatment), although all included studies evaluated CMV-specific HIG. Controlled studies showed no significant reduction in transmission (RR 0.73, 95% CI .54–1.00; P = .051) with moderate heterogeneity. The pooled transmission rate after HIG was 27.2%, with substantial heterogeneity. Current evidence does not support routine antenatal immunoglobulin to prevent cCMV.

19 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
KFKateryna Filonenko
Kateryna Filonenko
Marco PicardiMarco Picardi
Marco Picardi
Stephane ChauvieStephane Chauvie
Stephane Chauvie
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
MPMaria Cristina Pirosa
Maria Cristina Pirosa
Jan ZauchaJan Zaucha
Jan Zaucha
Radiation-free treatment for early-stage classic Hodgkin lymphoma (eHL) has been shown to be less effective than standard combined-modality treatment (CMT; chemotherapy plus involved-node radiotherapy (INRT)), which achieves long-term disease control of 94–95%. Approximately 70% of patients can be cured with chemotherapy alone, whereas about 5% fail CMT. Identifying patients who can safely receive chemotherapy alone and those requiring intensified CMT could enable a risk-adapted treatment strategy. The RAFTING trial (NCT04866654; EudraCT 2020-002382-33) is an international, prospective, phase 2, non-inferiority study enrolling patients 18–70 years, stage I–IIA eHL without bulky disease, B symptoms, or extranodal involvement. Low-risk (LR) patients are defined by total metabolic tumor volume (TMTV) <84 mL and negative PET-2. Those with at least one modified EORTC (mEORTC) risk factor, in which bulky disease is replaced by a large nodal mass (5–10 cm), receive four ABVD cycles, while those without risk factors receive two ABVD cycles alone. High-risk (HR) patients, defined by TMTV ≥84 mL and/or positive PET-2, receive “triple therapy”: 4 ABVD cycles, INRT (20/30 Gy), and nivolumab (240 mg q2w, ≤doses). LR patients are monitored using cfDNA. Limited relapse is treated with INRT (36 Gy) and nivolumab. The RAFTING trial is the first prospective eHL study to personalize treatment using TMTV and PET-2. It aims to omit radiotherapy in LR patients, intensify treatment in HR patients, and spare relapsed LR patients high-dose chemotherapy and autologous transplantation. CfDNA is being evaluated as a relapse marker. Despite the protocol’s complexity, this study exemplifies personalized medicine and could transform treatment practices.

13 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZBZuzanna Budzińska
Zuzanna Budzińska
ZBZofia Budzisz
Zofia Budzisz
MBMarta Maria Bednarek
Marta Maria Bednarek
JBJoanna Bidzinska
Joanna Bidzinska
The early diagnosis and treatment of civilizational diseases remain a significant challenge worldwide. Although advances in medical technology have led to the introduction of more screening options over time, these measures are still insufficient to effectively reduce mortality from deadly diseases such as lung cancer (LC), cardiovascular diseases (CVD), diabetes, and chronic obstructive pulmonary disease (COPD). These conditions pose a major public health burden, underlying the urgent need for more comprehensive and efficient prevention strategies. Recently, the concept of ‘multiscreening’ has emerged as a promising approach. Multiscreening involves the simultaneous screening for multiple diseases using integrated diagnostic methods, potentially improving early detection rates and optimizing resource utilization. In 2024, Rzyman W. et al. launched the MULTIPREVENT epidemiological study, which aims to develop and validate a low-dose computed tomography (LDCT)-based screening test for civilizational diseases. This study represents a step forward in the pursuit of more effective, minimally invasive diagnostic tools that could facilitate earlier intervention and improve patient outcomes. To better understand the potential of multiscreening approaches and their clinical utility, it is essential to evaluate the existing predictive models used for identifying individuals at high risk for these diseases. This narrative review focuses primarily on lung cancer risk prediction models used in LDCT screening while situating these approaches within the broader conceptual framework of the MULTIPREVENT project, aimed at future integration of multi-disease prevention strategies. With this analysis, we aim to provide insights that will guide the development of more accurate, integrative screening tools that could reduce the global burden of these diseases.

29 October 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MBMarta Maria Bednarek
Marta Maria Bednarek
MKMaria Komossa
Maria Komossa
JBJoanna Bidzińska
Joanna Bidzińska
Circulating cell-free DNA (cfDNA) and its tumor-derived fraction, circulating tumor DNA (ctDNA), enable non-invasive tumor genotyping, longitudinal disease monitoring, and molecular residual disease (MRD) assessment. Classical Hodgkin lymphoma (cHL) is particularly suitable for ctDNA-based analysis because malignant Hodgkin and Reed-Sternberg cells usually constitute only a small fraction of the tumor mass, whereas plasma may contain a strong tumor-derived DNA signal. This narrative review summarizes the potential applications of cfDNA-based ctDNA analysis in hematologic malignancies, with a focused emphasis on cHL. We discuss pre-analytical and analytical requirements, including plasma processing, tumor-informed and tumor-naive sequencing, error suppression, droplet digital PCR, and control for clonal hematopoiesis. We then synthesize evidence for ctDNA as a dual-readout biomarker: a baseline tool for non-invasive biological classification and a dynamic measure of molecular response. Published studies identify cHL genomic subtypes, associations with the tumor microenvironment, and prognostic information complementary to PET and conventional risk factors. Age-specific evidence is uneven, and most studies demonstrate analytical feasibility or prognosis rather than benefit from a ctDNA-triggered intervention. ctDNA-MRD should complement FDG-PET/CT; it cannot localize disease or currently replace established staging and response criteria. Routine implementation will require harmonized sample handling, validated assays and reporting thresholds, external quality assessment, and prospective trials demonstrating that ctDNA-guided treatment improves disease control, toxicity, or quality of life.